Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Familial long QT syndrome

Orpha number ORPHA768
Synonym(s) Congenital long QT syndrome
Prevalence Unknown
Inheritance Autosomal dominant
Autosomal recessive
Age of onset Childhood
ICD-10
  • I45.8
ICD-O -
OMIM
UMLS
  • C1141890
MeSH -
MedDRA
  • 10057926
SNOMED CT
  • 442917000

Summary

Congenital long QT syndrome (LQTS) is a hereditary cardiac disease characterized by a prolongation of the QT interval at basal ECG and by a high risk of life-threatening arrhythmias. Disease prevalence is estimated at close to 1 in 2,500 live births. The two cardinal manifestations of LQTS are syncopal episodes, which may lead to cardiac arrest and sudden cardiac death, and electrocardiographic abnormalities, including prolongation of the QT interval and T wave abnormalities. The genetic basis of the disease was identified in the mid-nineties and all the LQTS genes identified so far encode cardiac ion channel subunits or proteins involved in modulating ionic currents. Mutations in these genes (KCNQ1, KCNH2, KCNE1, KCNE2, CACNA1c, CAV3, SCN5A, SCN4B) cause the disease by prolonging the duration of the action potential. The most prevalent LQTS variant (LQT1) is caused by mutations in the KCNQ1 gene, with approximately half of the genotyped patients carrying KCNQ1 mutations. Given the characteristic features of LQTS, the typical cases present no diagnostic difficulties for physicians aware of the disease. However, borderline cases are more complex and require the evaluation of various electrocardiographic, clinical, and familial findings, as proposed in specific diagnostic criteria. Additionally, molecular screening is now part of the diagnostic process. Treatment should always begin with beta-blockers, unless there are valid contraindications. If the patient has a further syncopal episode despite a full dose beta-blockade, left cardiac sympathetic denervation (LCSD) should be performed without hesitation and implantable cardioverter-defibrillator (ICD) therapy should be considered with the final decision being based on individual patient characteristics (age, sex, clinical history, genetic subgroup including mutation-specific features in some cases, and the presence of ECG signs - including 24-hourHolter recordings - indicating high electrical instability). The prognosis of the disease is usually good in patients that are correctly diagnosed and treated. However, there are a few severe exceptions for patients with LQTS variants: patients with Timothy syndrome (characterised by marked QT interval prolongation, 2:1 functional atrioventricular block and syndactyly), Jervell and Lange-Nielsen syndrome patients carrying KCNQ1 mutations (a severe form of LQTS associated with congenital deafness and very early occurrence of cardiac arrhythmias) and LQT3 patients with 2:1 atrioventricular block and very early occurrence of cardiac arrhythmias (see these terms).

Expert reviewer(s)

  • Dr Giuseppe CELANO
  • Dr Lia CROTTI
  • Pr Peter SCHWARTZ

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Emergency guidelines
  • DE (2014,pdf)
  • IT (2008,pdf)
  • PT (2008,pdf)
  • ES (2008,pdf)
  • FR (2008,pdf)
Review article
  • EN (2008)
Clinical practice guidelines
  • FR (2009)
  • EN (2013)
Guidance for genetic testing
  • EN (2013,pdf)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.